Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization

被引:7
|
作者
Ventura, Yossi [1 ,2 ]
Carr, Brian I. [3 ]
Kori, Issac [4 ]
Guerra, Vito [5 ]
Shibolet, Oren [1 ,2 ]
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Gastroenterol & Hepatol, Liver Unit, 14 Weizman St, IL-62431 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[3] Dokuz Eylul Univ, Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey
[4] Tel Aviv Med Ctr & Sch Med, Div Imaging, Intervent Radiol, IL-62431 Tel Aviv, Israel
[5] IRCCS Bellis, Dept Clin Trials & Epidemiol, I-70013 Castellana Grotte, Italy
关键词
Hepatocellular carcinoma; Aggressiveness index; Liver function; Transarterial chemoembolization; Survival; GAMMA-GLUTAMYL-TRANSPEPTIDASE; PREDICT SURVIVAL; PROGNOSTIC VALUE; SCORES; EMBOLIZATION; INDEX;
D O I
10.3748/wjg.v24.i15.1641
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM To investigate novel predictors of survival in hepatocellular carcinoma (HCC) patients following transarterial chemoembolization (TACE). METHODS One hundred sixty seven patients with un-resectable HCC were retrospectively analyzed to identify factors that might contribute to their HCC biology and aggressiveness. We correlated routine laboratory results (total bilirubin, AST, ALKP, GGTP, albumin etc.) to maximum tumor diameter, number of tumor nodules, portal vein thrombosis and blood alpha-fetoprotein levels. These 4 parameters were previously combined to form an aggressiveness index (AgI). We used The Wilcoxon ranksum (Mann-Whitney), to test the correlation between the AgI categories and liver function parameters. The Cox proportional hazards model was applied to evaluate the categories of AgI associated with overall survival. RESULTS The AgI was strongly correlated with survival in this novel patient population. Three year survival probability for AgI > or < 4 was 42.4% vs 61.8%; p < 0.0863 respectively. Several factors independently correlated with AgI using univariate multiple logistic regression of AgI with 8 laboratory parameters. Lower albumin levels had an OR of 2.56 (95% CI: 1.120-5.863 p < 0.026), elevated Alkaline phosphatase and gamma glutamyl transpeptidase (GGTP) had ORs of 1.01 (95% CI: 1.003-1.026, p < 0.017) and 0.99 (95% CI: 0.99-1.00, p < 0.053) respectively. In a Cox proportional hazard model combining mortality for AgI score and liver function parameters, only GGTP levels and the AgI were independently associated with survival. An AgI > 4 had HR for mortality of 2.18 (95% CI: 1.108-4.310, p < 0.024). GGTP's single unit change had a HR for mortality of 1.003 (95% CI: 1.001-1.006, p < 0.016). These were considered in the final multivariate model with the total cohort. An AgI > 4 had a HR for mortality of 2.26 (95% CI: 1.184-4.327, p < 0.016). GGTP had a HR of 1.003 (95% CI: 1.001-1.004, p < 0.001). CONCLUSION Our study validates the AgI in a new population with un-resectable HCC patients undergoing TACE. The analysis establishes a correlation between GGTP and the AgI.
引用
收藏
页码:1641 / 1649
页数:9
相关论文
共 50 条
  • [31] Transarterial Chemoembolization Treatment Paradigms for Hepatocellular Carcinoma
    Fite, Elliott L.
    Makary, Mina S.
    CANCERS, 2024, 16 (13)
  • [32] Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Renal Insufficiency
    Hsu, Chia-Yang
    Huang, Yi-Hsiang
    Su, Chien-Wei
    Chiang, Jen-Huey
    Lin, Han-Chieh
    Lee, Pui-Ching
    Lee, Fa-Yauh
    Huo, Teh-Ia
    Lee, Shou-Dong
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2010, 44 (08) : E171 - E177
  • [33] Current concepts in transarterial chemoembolization of hepatocellular carcinoma
    Huppert, Peter
    ABDOMINAL IMAGING, 2011, 36 (06): : 677 - 683
  • [34] Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma
    Jie Wu
    Lei Song
    Dan-Yi Zhao
    Bing Guo
    Jing Liu
    World Journal of Gastroenterology, 2014, (31) : 10960 - 10968
  • [35] Transarterial chemoembolization prior to liver transplantation for patients with hepatocellular carcinoma: A meta-analysis
    Si, Tengfei
    Chen, Yongjun
    Ma, Di
    Gong, Xiaoyong
    Guan, Ruoyu
    Shen, Boyong
    Peng, Chenghong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (07) : 1286 - 1294
  • [36] Hepatocellular Carcinoma Rupture Following Transarterial Chemoembolization
    Bhinder, Nimarta Singh
    Zangan, Steven M.
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2015, 32 (01) : 49 - 53
  • [37] Adjuvant transarterial chemoembolization for patients with hepatocellular carcinoma involving microvascular invasion
    Qi, Ya-Peng
    Zhong, Jian-Hong
    Liang, Zhi-Yin
    Zhang, Jie
    Chen, Bin
    Chen, Chang-Zhi
    Li, Le-Qun
    Xiang, Bang-De
    AMERICAN JOURNAL OF SURGERY, 2019, 217 (04) : 739 - 744
  • [38] Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma
    Kong, Jie-Yu
    MEDICINE, 2018, 97 (33)
  • [39] Radiomic advances in the transarterial chemoembolization related therapy for hepatocellular carcinoma
    Chen, Tian-You
    Yang, Zong-Guo
    Li, Ying
    Li, Mao-Quan
    WORLD JOURNAL OF RADIOLOGY, 2023, 15 (04): : 89 - 97
  • [40] Transarterial chemoembolization for hepatocellular carcinoma: a bibliometric analysis of the most cited articles
    Das, J. P.
    Thulasidasan, N.
    Ahmed, I
    Diamantopoulos, A.
    JAPANESE JOURNAL OF RADIOLOGY, 2020, 38 (12) : 1190 - 1196